The population-attributable fraction (PAF) is an indicator of the disease burden. In Western countries, the PAF of hypercholesterolemia in cardiovascular disease (CVD) is the highest among that for traditional risk factors; however, data for Asian populations are limited. Methods: A 24-year cohort study was conducted among 9,209 randomly selected participants who were not taking statins. We estimated the hazard ratio (HR) after adjusting for covariates and PAF associated with the serum total cholesterol (TC) levels in relation to CVD mortality. Results: The TC level was found to be positively associated with an increased risk of CVD, coronary heart disease (CHD) and cardiac death (CHD plus heart failure), with an HR of 1.08 (95% confidence interval [CI]: 1.00-1.16), 1.33 (95% CI: 1.14-1.55) and 1.21 (95% CI: 1.08-1.35) for a 1-SD increment in the serum TC level, respectively. Similar positive associations between the TC level and both CHD and cardiac death were observed after classifying the patients by age and sex. Furthermore, the highest serum TC level (≥ 6.72 mmol/L) was positively associated with CVD death, with an HR of 1.76 (95% CI: 1.25-2.47), as well as both CHD death and cardiac death. In contrast, no significant relationships were observed between the serum TC level and stroke. Meanwhile, the PAF for CVD, CHD, and cardiac deaths due to hypercholesterolemia (serum TC level ≥ 5.69 mmol/L, defined by the Japan Atherosclerosis Society) was 1.7%, 10.6% and 5.6%, respectively. Conclusions: The estimated PAF of CVD death due to hypercholesterolemia is moderately high, but lower than that for other risk factors, such as hypertension.
Introduction
Cardiovascular diseases (CVDs), such as coronary heart disease (CHD), are common causes of death in developed countries, including Japan 1) , and a high serum total cholesterol (TC) level is an established risk factor for CVD. The population attributable fraction (PAF) is the proportional reduction in mortality that would occur if the exposure to a risk factor were to be reduced to an alternative ideal level, a parameter that can be used in the management of CVD patients. In studies from Western countries, the PAF of CVD mortality due to hypercholesterolemia is highest among that for traditional risk factors [2] [3] [4] ; however, evidence of this relationship in Asian countries, including Japan, in which the CHD incidence is low, is scarce 5) . Specifically, the effects of a high serum TC level on the health of the general Japanese population in the context of disease burden is unknown.
Several Japanese studies have estimated the PAF of CVD death based on established CVD risk factors 6, 7) , such as smoking and hypertension. However, to the best of our knowledge, no observational studies with a long-term follow-up period of 20 years estimating the PAF for CVD death due to hypercholesterolemia have been conducted in Japan or other Asian countries. We previously reported the relationship between TC and CVD based on the findings of the National Integrated Project for Prospective Observation of Non-communicable Disease And its Trends in the Aged, 1980 (NIPPON DATA80), trial, with followup examinations conducted at 14 and 19 years after study initiation (until 1994 and 1999, respectively) 8, 9) . However, we did not calculate the PAF of CVD caused by hypercholesterolemia.
Therefore, in the current study, we investigated the relationship between the serum TC level and mortality due to CVD in the NIPPON DATA80 cohort with a longer follow-up period than that used in the former study 8, 9) and estimated the PAF of death due to CVD attributable to a high serum TC level.
Methods

Population
The subjects in this cohort were also participants sured using the hexokinase method, this parameter was adjusted using the following formula: [0.047 (glucose concentration in mg/dL) 0.541] 17) . Diabetes was defined as a non-fasting serum glucose level of ≥ 11.1 mmol/L, history of diabetes or both. Height in stocking feet and weight in light clothing were measured. Questionnaires responses regarding smoking and drinking habits and medical history were analyzed by public health nurses.
Statistical Analysis
The serum TC levels were categorized into the following seven categories: 4.14, 4.14-4.65, 4.66-5. 16 , 5.17-5.68, 5.69-6.20, 6.21-6.71 and ≥ 6.72 mmol/L. The participants with a serum TC level of 4.14-4.65 mmol/L formed the reference group. These categories were determined based on the results of our previous study, which provided key evidence for the guidelines for the diagnosis and prevention of atherosclerosis and CVD in the Japanese population issued by the Japan Atherosclerosis Society (JAS) 8) . Cox proportional hazard models were used to estimate the relative risk as the hazard ratio (HR) for death due to CVD according to one standard deviation (SD), i.e., a
Baseline Examinations
The baseline surveys were conducted at public health centers using criteria from a standardized manual. Non-fasting blood samples were drawn and centrifuged within 60 minutes of collection and stored at 70 until the analyses. As previously reported, the serum TC and albumin levels were analyzed at a single central laboratory (present name: Osaka Medical Center for Health Science and Promotion) using an autoanalyzer (SMA12/60; Technicon, Tarrytown, USA). Since April 1975, the precision and accuracy of the cholesterol measurements obtained in this laboratory have been certified by the CDC-NHLBI Lipid Standardization Program of the Center for Diseases Control and Prevention 16) . Trained research nurses measured the blood pressure of the seated subject using a standard mercury sphygmomanometer on the right arm after five minutes of rest. Hypertension was defined as a systolic blood pressure of ≥ 140 mmHg, diastolic blood pressure of ≥ 90 mmHg, use of antihypertensive drugs, history of hypertension or any combination of these findings. The serum glucose level was measured using the cupric-neocuproine method. Since the serum glucose level is more commonly mea- [Proportion of cases exposed to risk factor (Adjusted HR-1)/Adjusted HR].
The PAFs for the TC categories ≥ 5.69 mmol/L (according to the definition of "hypercholesterolemia" provided by the JAS) 19) and ≥ 6.21 mmol/L (according to the definition provided by the adult treatment panel by the National Cholesterol Education Program, United States: ATP ) were estimated as the excess death fractions due to a high TC level. We recalculated the adjusted HR for each hypercholesterolemia case in order to estimate the PAFs.
All statistical analyses were performed using the 0.87 mmol/L increment in the baseline serum TC level. We evaluated the HRs for total CVD, CHD, cardiac death, stroke and cerebral infarction. In the Cox regression model, age, serum albumin, body mass index (BMI), hypertension, diabetes, smoking status (never-smoker as the reference, ex-smoker, current smoker ≤ 20 and smoker ≥ 20 cigarettes/day) and drinking status (never-drinker as the reference, exdrinker, occasional drinker and daily drinker) were adjusted. We also estimated the HRs according to a Cox model assessing the serum TC level with reference to the seven categories described above. Violation of the proportional hazard assumption was determined using Schoenfeld residuals. Tests for interactions between sex, age ( 65 or ≥ 65 years), hypertension, current smoking and BMI ( 25 or ≥ 25 kg/m 2 ) were conducted with an interaction term generated by multiplying the continuous serum TC level by the cardiovascular risk factors described above. Tests for interactions were performed for death due to CVD, SD: standard deviation, HR: hazard ratio, 95% CI: 95% confidence interval, CVD: cardiovascular disease, CHD: coronary heart disease, HF: heart failure The HRs were adjusted according to age, sex, the serum albumin level, body mass index, hypertension, diabetes, smoking status and drinking status. ent among the TC categories only in men.
The total person-years were 193,022 years and the mean follow-up period was 21.0 5.8 years (mean SD). During the follow-up period, there were 2,566 total deaths (1,365 men and 1,201 women), with 884 deaths due to CVD (34%), including 172 deaths due to CHD (7%), 176 deaths due to heart failure (7%) and 411 deaths due to stroke (16%). The deaths due to stroke also included 241 cerebral infarction-related deaths (9%).
The number of deaths, person-years and multivariable adjusted HRs for the CVD-related deaths according to a 1-SD increment in the serum TC level and the seven TC level categories in all subjects are summarized in Table 2 . Consequently, a 1-SD increment in the serum TC level was found to be positively associated with an increased risk of CVD death (HR: 1.08, 95% CI: 1.00-1.16). The positive relationships between a 1-SD increment in the serum TC level and an increased risk of CHD death and cardiac death R version 2.15 software program (R Foundation for Statistical Computing, Vienna, Austria). All confidence intervals (CIs) were estimated at the 95% level, and statistical significance was defined as a p value of 0.05.
Results
The means and prevalence of the baseline characteristics of all subjects in each TC category based on sex are summarized in Table 1. The mean serum TC level was 4.88 0.87 mmol/L overall (mean SD), 4.93 0.88 mmol/L in women and 4.81 0.85 mmol/ L in men. The mean age of the subjects in this study was 50.0 13.2 years overall, 50.1 13.3 years in women and 49.7 13.1 years in men. Age, the serum albumin level, BMI and the prevalence of hypertension and diabetes were statistically different in each TC category for both sexes, whereas the proportion of current smokers and drinkers was significantly differ- by age and sex are summarized in Table 3 . The relationship between a 1-SD increment in the serum TC level and death due to CHD and/or cardiac death was very similar to that observed in the overall analysis. Specifically, we showed that a 1-SD increment in the serum TC level was positively associated with cardiac death in both age categories ( 65 or ≥ 65 years) and sexes (women and men). There were no interactions with age or sex in the associations between the TC level and each endpoint, i.e., CVD, CHD and cardiac death. In Table 4 , we present the multivariable HRs obtained after stratifying the patients by other risk factors, including hypertension, smoking and BMI. The results of these analyses were similar to those of the over analysis and the analyses performed following classification based on age or sex. There were no interactions with hypertension or BMI in the associations were also noted. The HRs for CHD and cardiac death were 1.33 (95% CI: 1.14-1.55) and 1.21 (95% CI: 1.08-1.35), respectively. Alternatively, deaths due to stroke and cerebral infarction were not associated with a 1-SD increment in the serum TC level. In the analyses of the seven TC level categories, we found a positive association between the highest TC level category and an increased risk of CVD death (HR: 1.76, 95% CI: 1.25-2.47). An increased risk of CHD death and cardiac death was also observed in the highest TC level category. The HR was 3.52 (95% CI: 1.89-6.57) for CHD death and 2.68 (95% CI: 1.64-4.38) for cardiac death. Meanwhile, death due to stroke and/or cerebral infarction was not associated with any TC level category. There were no significant violations of the proportional hazard assumption in these models.
The results obtained after classifying the subjects (Cont Table 3 smokers than in the non-smokers (Table 4) . We also calculated the population-attributable risk fractions for CVD, CHD and cardiac death, although the HRs for CVD were not significant ( Table 5 ). The number of estimated excess deaths due between the TC level and each endpoint; however, the interaction term between the serum TC level and current smoking was significant for CHD death (p 0.02). In addition, the multivariable HR for CHD based on the serum TC level was higher in the current SD: standard deviation, HR: hazard ratio; 95% CI: 95% confidence interval, CVD: cardiovascular disease, CHD: coronary heart disease, HF: heart failure The HRs were adjusted based on the following factors: A. age, sex, the serum albumin level, body mass index, diabetes, smoking status and drinking status B. age, sex, the serum albumin level, body mass index, hypertension, diabetes and drinking status C. age, sex, the serum albumin level, body mass index, hypertension, diabetes, smoking status and drinking status tries, the estimated PAF of CVD death due to hypercholesterolemia was found to be the highest among that for other risk factors [2] [3] [4] . However, the estimated PAFs in our study were lower than those for other risk factors, such as smoking (29%) and hypertension (8%), reported in previous studies assessing Japanese populations 6, 7)
. Generally, the serum TC levels are lower in Asia countries, including Japan, than in Western countries 20, 21) . This observation may reflect the different impact of PAF of CVD death due to hypercholesterolemia. Furthermore, the reason for this difference appears to be due to differences in the prevalence of CHD and stroke in the Japanese population. Compared to that observed in Western countries, the prevalence of CHD is lower than that of stroke in Japan 20) . Moreover, as demonstrated in this study, hypercholesterolemia is not related to stroke mortality, although hypertension, smoking and diabetes are positively associated with stroke as well as CHD. Consequently, these factors resulted in lower PAFs due to hypercholesterolemia than those due to other risk factors in the present study.
As described above, neither a 1-SD increment nor high serum TC level were found to be associated with death due to stroke. This observation is consistent with the findings of other studies conducted in Japan [22] [23] [24] . In Japan, hypertension is the strongest risk factor for stroke; therefore, the influence of hypercholesterolemia is thought to be relatively weak 25) . Moreover, one subtype of stroke, atherothrombotic infarction, is positively associated with hypercholesterolemia, although its incidence among stroke cases is relatively low in Japan 26, 27) . This may be why hypercholesterolemia is not positively associated with stroke in Japan. The absence of a positive association between the cholesterol levels and stroke mortality has also been noted in studies in Western countries, especially to hypercholesterolemia was 14.6, 18.2 and 19.5 for CVD, CHD and cardiac death, respectively. The PAF of hypercholesterolemia determined based on the JAS definition (TC level ≥ 5.69 mmol/L) was 1.7%, 10.6% and 5.6% for CVD, CHD and cardiac death, respectively. Using the ATP definition (a TC level of ≥ 6.21 mmol/L), the PAFs for CVD, CHD and cardiac death were 1.7%, 6.9% and 4.6%, respectively. The number of excess deaths was also estimated to be 14.6 for CVD, 11.9 for CHD and 15.6 for cardiac death.
Discussion
In this 24-year Japanese cohort study, we found a 1-SD increment in the serum TC level to be positively associated with an increased risk of CVD, CHD and cardiac death. Similar results were also observed after classifying the participants by age ( 65 or ≥ 65 years) and sex. Moreover, in the analyses of the seven TC level categories, the highest TC level (≥ 6.72 mmol/L) was found to be significantly associated with an increased risk of death due to CVD, especially CHD and cardiac death, and the PAFs of these diseases were moderately high. Furthermore, the relationship between the serum TC level and cardiovascular outcome was similar to that observed after classifying the subjects based on other risk factors, such as the prevalence of hypertension and current smoking. To the best of our knowledge, this is the first study to estimate the PAF for CVD death due to a high serum TC level in a Japanese population with a long follow-up period. Our results were based on data collected in 1980 and were not influenced by statins, as these drugs were not available in the market at the time of the survey.
In previous studies conducted in Western coun- we were unable to obtain detailed information regarding the subtypes of stroke and heart failure because we could not view the subjects' death certificates. In Japan, the single underling cause of death is determined according to the ICD-9 code (until 1994) or ICD-10 code (from 1995 onwards) by a government officer based on a review of the death certificate. However, we believe this process may minimize the potential for information bias because the endpoints of NIPPON DATA were not defined by the researchers themselves. Third, we did not have access to data for other lipid parameters, such as high-density lipoprotein cholesterol, because the lipid profiles, with the exception of the TC level, were not generally evaluated in Japan during the baseline survey period.
Conclusion
In conclusion, in this long-term cohort study, hypercholesterolemia was shown to be significantly associated with an increased risk of death due to CVD, especially CHD and CHD plus HF, in both sexes among middle-aged and elderly communitydwelling Japanese individuals. The estimated PAFs of these diseases due to hypercholesterolemia were lower than those noted in Western countries and the values for other traditional risk factors. Nevertheless, we believe than managing hypercholesterolemia in Japanese is necessary in order to prevent the development of CVD in these populations.
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Moreover, we found a significant interaction between the serum TC level and smoking for CHD death, and the HR for smoking was higher than that for non-smoking in the subgroup analysis. These results are consistent with those reported by the Asia Pacific Cohort Studies Collaboration 29) and NIPPON DATA80 30) studies, although such findings have not been observed consistently 31) . Further research is therefore needed to confirm our findings.
As demonstrated in previous studies 8, 9) , hypercholesterolemia is an important risk factor for CHD in Japan. However, the rate of fatalities from CHD among the Japanese population is lower than that observed in Western countries [32] [33] [34] . Heart failure is representative of end-stage CHD; therefore, HF may be registered as the cause of death in patients with CHD who survive a heart attack. Shiba et al. showed that the frequency of HF with an ischemic etiology is increasing in Japan 35) . Hence, we evaluated the endpoint "cardiac death," defined as death due to CHD or HF, and observed a similar result as that obtained for CHD only. Notably, the estimated PAF of CHD was higher than that of cardiac death, although this trend reversed when considering the estimated number of excess deaths.
As mentioned above, although the PAFs for smoking and hypertension estimated in other studies 6) are very high (29%), the rate of smoking is currently decreasing in Japan, and the prevalence of hypertension has not changed, even after adjusting for age 36, 37) . In contrast, the incidence of hypercholesterolemia is increasing 37) . As a result, the PAF of hypercholesterolemia may be higher in the future than that estimated in this study. Moreover, because the generation with hypercholesterolemia is reaching an age at which the risk for CVD increases, treating hypercholesterolemia is becoming increasingly important.
This study is associated with several limitations. First, we assessed risk factors, including the serum TC level, at baseline only; therefore, the relationship between the serum TC level and mortality may have been underestimated due to random errors in measuring the serum TC levels, known as the regression dilution effect 38) . Moreover, we did not have any information regarding changes in lifestyle or medications among the study subjects. For these reasons, it is necessary to apply the PAFs determined in this study to the present Japanese population with caution. Second,
